Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.34 - $142.00
Previous CloseN/A
Volume488.69K
Average Volume (3M)3.71M
Market Cap
$35.36B
Enterprise Value$27.60B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)63.0
Beta1.03
Next Earnings
Apr 24, 2025EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.42
Shares Outstanding390,772,000
10 Day Avg. Volume4,180,190
30 Day Avg. Volume3,713,856
Standard Deviation0.14
R-Squared0.18
Alpha0.00239
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.86
Price to Cash Flow (P/CF)43.90
P/FCF Ratio96.10
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.19
Enterprise Value/Ebitda30.19
Forecast
1Y Price Target
$101.65Price Target Upside13.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityDexcom exited 2024 with $2.58 billion in cash, cash equivalents, and marketable securities, providing financial and strategic flexibility for expansion.
Market Coverage ExpansionTwo of the three largest PBMs now cover DXCM's CGM for anybody with diabetes as of January 2025, creating access for 5 million new T2 non-IIT patients, which could serve as a potentially meaningful growth driver.
Bears Say
Rebate Eligibility ImpactRebate eligibility negatively impacted Dexcom's US growth rate by several points in the recent quarter.
---
Ownership Overview
0.42% Insiders
28.42% Mutual Funds
26.18% Other Institutional Investors
15.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $35.36B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Apr 24, 2025 which is in 61 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Feb 13, 2025. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.479 by -$0.029.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.33.
How many shares outstanding does Dexcom have?
Dexcom has 390,772,000 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.45 in its last earnings report, missing expectations of $0.479. Following the earnings report the stock price went up 5.922%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$101.65 (13.78% Upside)
$101.65 (13.78% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 73%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 139.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.20%
12-Months-Change
Fundamentals
Return on Equity
27.63%
Trailing 12-Months
Asset Growth
3.51%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for DexCom, with strong revenue growth, significant customer base expansion, and successful international market performance. However, challenges such as gross margin decline and operating income reduction were noted, indicating areas for improvement.Read More>---
DXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$101.65
▲(13.78% Upside)
Technical Analysis
Abbott Laboratories
―
Insulet
―
Medtronic
―
Tandem Diabetes Care
―
Senseonics Holdings
―
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
18/24 ratings generated profit
1 Year Average Return
+26.09%
reiterated a buy rating 8 days ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +26.09% per trade.
---